Active Biotech AB Interim report January – June 2021

Good progress in the projects towards important clinical events

SECOND QUARTER IN BRIEF

• Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab

EVENTS AFTER THE END OF THE PERIOD

• Active Biotech provided status update on the progress in its clinical naptumomab project
• Active Biotech’s partner NeoTX hosted KOL webinar on overcoming checkpoint inhibitor resistance, featuring combination with naptumomab as one approach

Financial summary  

For further information, please contact:

The report is also available at www.activebiotech.com.

Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. This information was provided to the media, through the agency of the contact person set out above, for publication on August 5, 2021, at 08.30 a.m. CET.

Attachment

• Active Biotech Interim Report Jan-Jun 2021